Baiotai: BAT3306 and BAT8008 jointly approved for clinical trials.

Baiotai announced that the company recently received the "Clinical Trial Approval Notice" issued by the National Medical Products Administration. The company's clinical trial application for the combination injection of drug BAT3306 and BAT8008 for the treatment of advanced solid tumor patients has been approved. Among them, BAT3306 is a biosimilar of pembrolizumab, and BAT8008 is an antibody-drug conjugate targeting Trop2. The company emphasized that further clinical trials are still required for the drug, and data must be approved before it can be marketed. There is uncertainty in the research and approval results, so investors are advised to pay attention to the risks.